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ABSTRACT
RNA-interference-driven loss of function in specific
tissues in vivo should permit analysis of gene
function in temporally and spatially defined con-
texts. However, delivery of efficient short hairpin
RNA (shRNA) to target tissues in vivo remains
problematic. Here, we demonstrate that efficiency
of polyethylenimine (PEI)-delivered shRNA depends
on the regulatory sequences used, both in vivo and
in vitro. When tested in vivo, silencing of a
luciferase target gene by shRNA produced from a
hybrid construct composed of the CMV enhancer/
promoter placed immediately upstream of an
H1 promoter (50%) exceeds that obtained with
the H1 promoter alone (20%). In contrast, in NIH
3T3 cells, the H1 promoter was more efficient than
the hybrid construct (75 versus 60% inhibition
of target gene expression, respectively). To test
CMV-H1 shRNA efficiency against an endogenous
gene in vivo, we used shRNA against thyroid
hormone receptor a1 (TRa1). When vectorized in
the mouse brain, the hybrid construct strongly
derepressed CyclinD1-luciferase reporter gene
expression, CyclinD1 being a negatively regulated
thyroid hormone target gene. We conclude that
promoter choice affects shRNA efficiency distinctly
in different in vitro and in vivo situations and that a
hybrid CMV-H1 construct is optimal for shRNA
delivery in the mouse brain.
INTRODUCTION
RNA interference (RNAi) is now a well-described
mechanism by which a double-stranded RNA (dsRNA)
leads to the sequence-speciﬁc inhibition of its homologous
gene. First described in plants (1), it has since been applied
to numerous invertebrate and vertebrate models (2). In
mammalian cells, the introduction of long dsRNAs
into mammalian cells activates protein kinase PKR and
RNase L, leading to an interferon response and hence to
the non-speciﬁc extinction of genes resulting in cell death
(3,4). This non-speciﬁc eﬀect of long dsRNAs into
mammalian cells can be bypassed by using small RNA
duplexes of 19–21nt, which are suﬃcient to trigger speciﬁc
RNAi in mammalian cells without activating the inter-
feron response (5).
This highly eﬃcient and speciﬁc technology opens up a
broad spectrum of experimental and therapeutic possibi-
lities (6,7). However, the lack of suitable delivery systems
for short interfering RNAs (siRNAs) in vivo has
hampered the advance of such applications.
To date two main methods have been developed to
obtain suﬃcient intracellular levels of RNAi for gene
silencing in mammals in vivo. The ﬁrst method involves
direct vectorization of siRNA into the target cell. The
alternative is to vectorize plasmids containing short
hairpin RNA (shRNA) cassettes, which leads to shRNA
transcription, followed by Dicer-dependent loop cleavage
and siRNA production. Most often, the promoters used
to direct the expression of the shRNAs are H1 (8) and U6
(9–11) or CMV (12). So far these promoter systems have
been tested with a variety of viral delivery systems
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lentiviruses (15). However, there are only few reports of
their use with non-viral delivery of shRNA-carrying
plasmids, neither in vitro nor in vivo.
We previously demonstrated that cationic lipids could
provide eﬃcient delivery of siRNAs into the brain of
newborn mice brains, producing 480% inhibition of an
exogenous gene with only 5 pmol of siRNAs (16).
However, generally speaking cationic lipoplexes are less
eﬃcient than polyplexes for plasmid vectorization in vivo.
For instance in the adult mammalian brain, the cationic
polymer polyethylenime (PEI), and particularly linear
22-kDa PEI (L-PEI), easily outclasses other lipid- or
polymer-based vectors (16) [for review see (17)]. We thus
chose to use PEI vectorization to evaluate the capacity of
two diﬀerent constructs: either H1 alone or a hybrid CMV
enhancer and minimal promoter/H1 promoter construct
(hereafter called the CMV/H1 construct). Each construct
was tested for its capacity to direct the expression of
shRNA-carrying plasmids in vitro and in vivo in the brains
of newborn and adult mice.
We show that, when tested in vitro on two diﬀerent cell
lines, the eﬃciency of target silencing is independent of
the promoter used. In contrast, when tested in vivo in
either the developing or the adult brain, the eﬃciency of
the shRNAs depends markedly on the promoter used to
drive production. We found that the H1-shRNA
construct provided only a slight decrease in luciferase
target gene expression. However, surprisingly, we found
that the hybrid CMV-H1 construct directing shRNA
production provided a signiﬁcant inhibition of the
co-transfected luciferase gene in both in vivo situations
tested.
Further, we tested the eﬃciency of a shRNA directed
against endogenous thyroid hormone a1 (shTRa1) in cell
cultures and in the newborn mouse brain. We ﬁrst
demonstrated that the shTRa1 eﬃciently inhibits the
expression of endogenous TRa1 in cell culture. Then we
show that the presence of the shTRa1-carrying plasmid in
the newborn mouse brain strongly increases the expression
of a co-transfected CyclinD1-luciferase reporter gene,
CyclinD1 being a negatively regulated thyroid hormone
target gene in our experimental paradigm. These data
demonstrate that shRNAs under the control of a hybrid
CMV-H1 construct eﬃciently inhibit endogenous gene
expression in vivo, and that this technology can be
used for further gene function analysis in the brain of
newborn mice.
METHODS
Plasmid constructions and siRNAs
The Renilla reniformis (RLluc)- and Photinus pyralis
(PPluc)-luciferases carrying plasmids are respectively
pRL-CMV (Promega) and a pGL2-basic vector with a
cytomegalovirus (CMV) promoter inserted in the multiple
cloning site referred in the following as pGL2-CMV. The
shRNA sequence directed against pGL2 luciferase (shLuc
in the text) is the following: 50CGTACGCGGAATACT
TCGATTCAAGAGATCGAAGTATTCCGCGTACG30.
The H1-shLuc construction based on a pSUPERbasic
backbone (8) was kindly provided by Dr A Harel-Bellan
(Institut Andre ´ Lwoﬀ, Villejuif, France).
For the CMV-H1-shLuc construction, the H1-shLuc
plasmid was digested by BamH1 and HindIII. The 280-bp
insert containing the shLuc and the H1 promoter
sequences was inserted into the luciferase-free pRL-
CMV vector obtained after the digestion of pRL-CMV
with PstI and XbaI. This digestion releases the Renilla
luciferase gene sequence but conserves the full CMV
enhancer and early promoter. The selected clones were
sequenced using the CMV forward primer (MWG
Biotech). One clone, clone 6 was found to carry both the
shLuc sequence and the H1 promoter just following the
CMV enhancer/early promoter (see scheme, Figure 1).
The CMV-shLuc construction was obtained by ligation
of a synthetic double-stranded oligonucleotide shLuc
carrying PstI and XbaI ends (Eurogentec) inside the
PstI/XbaI sites of pRL-CMV.
Two 21-nt-long double-stranded siRNA targeted to
ﬁreﬂy luciferases siLuc and siLucmt were synthesized
according to the sequences previously described (5,16).
For the inhibition of TRa1, we designed a 21-bp sequence
directed against a speciﬁc sequence for TRa1 gene
(siTRa1). The sequence of the siTRa1 was the
following: siTRa1(up): 50CGCUCUUCCUGGAGGUC
UUTT30; siTRa1(down): 50AAGACCUCCAGGAAGA
GCGTT30. For the CMV-H1-shTRa1 construction,
we designed a 100-bp palindromic sequence based on
the siTRa1 sequence and containing an 8-bp loop
(TCAAGAG). This 100-bp sequence was designed with
Bsa1 and Not1 cohesive ends, which allowed its insertion
inside the Bsa1/Not1 site of CMV-H1-shLuc plasmid
where the shLuc sequence was deleted previously.
Preparation of complexes and gene transfer invivo
All animal experiments were conducted in accordance
with the principles and procedures described in Guidelines
for Care and Use of Experimental Animals.
DNA was complexed L-PEI 22kDa with a 6N/P charge
ratio (where N¼the positive charges carried by proton-
able amines of PEI and P¼the negative charges carried by
DNA phosphates). For this, 0.18ml of L-PEI 100mM
were added per mg of DNA used. All solutions were
prepared in 5% glucose.
The protocol of stereotaxic injection into the lateral
ventricles of newborn mice brains was as described
previously. Brieﬂy, 2ml of a solution containing 0.1mgo f
each luciferase (i.e. pGL2-CMV and pRL-CMV) and
0.2–0.8mg of either the shLuc-containing plasmid tested or
a plasmid carrying an irrelevant shRNA under a CMV
enhancer/promoter, were stereotaxically injected into the
lateral ventricles of newborn mice brains. Here, 24–72h
post-transfection, the animals were dissected, the brains
were removed and the dual luciferase assay was performed
to detect the activity of Photinus (pGL2) and Renilla
(pRL) luciferases separately. Five animals were injected
per group, and the two hemispheres were analysed
separately for reporter gene expression (i.e. n¼10 hemi-
spheres per group). Each experiment was performed at
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shown SEM. Unpaired Student’s t-test or a non-
parametric Wilcoxon test were used for statistical
comparison between the control and treated groups.
For analysis of CyclinD1 expression, we used
a luciferase reporter gene under the control of a
CyclinD1 promoter. In each group, 0.5mg of CyclinD1-
luciferase plasmid was injected per hemisphere, along
with either 0–200 nM of siTRa1, or 0.2–0.5mg of CMV-
H1-shTRa1 plasmid. Note that the total amount of
nucleic acids transfected was constant in each experi-
ment, as appropriate quantities of siGFP (siRNA
directed against green ﬂuorescent protein) were added
bringing the ﬁnal siRNA concentration in all cases to
200 nM. Likewise, in the experiments using CMV-H1-
shTRa1, the total amount of plasmids injected was 1mg
per hemisphere. The irrelevant plasmid used to complete
the total amount of nucleic acids in the diﬀerent groups
of the shTRa1 experiment was the empty pcDNA3
(Invitrogen). In these experiments, 10 animals were
injected per group and the two hemispheres were
quantiﬁed separately for reporter gene expression (i.e.
n¼20 per group). Each experiment was performed at
least twice providing similar results. Means SEM are
shown. Statistical analysis was done using unpaired
Student’s t-test or a nonparametric Wilcoxon test for
comparison between the control and treated groups.
Cellculture studies
Human carcinoma cells (HeLa, HeLaX1/5 and
HeLa2053) and mouse ﬁbroblastic cells (NIH 3T3) were
cultured in complete growth medium (Dulbecco’s mod-
iﬁed Eagle’s medium supplemented with 10% (v/v) foetal
calf serum (FCS), 100mg/ml penicillin and streptomycin)
at 378C with 5% CO2. One day prior to transfection,
20 10
4 cells were plated in 48-well plates. The next day,
the medium was replaced by reduced serum medium
(Opti-MEM, Invitrogen). Each well was incubated with a
100ml transfection mix containing pRL-CMV and pGL2-
CMV (both at 30ng), and 0.37ml Lipofectamine
2000 reagent (Invitrogen), either with 250ng pshRNA
plasmids or 70ng siRNAs in 400ml Opti-MEM for 4h.
HeLaX1/5 cells, which stably expressed ﬁreﬂy luciferase
protein under the control of TetOFF-inducible promo-
ter (18) was co-transfected similarly using shRNA
carrying plasmids (250ng) and pRL-CMV (0.1mg). After
the incubation period, the transfection was stopped by
adding 500ml of complete medium with 20% FCS. After
24h incubation, cells were washed with PBS and lysed by
adding passive lysis buﬀer (Promega). An aliquot of the
lysate was assayed for protein concentration (BioRad)
and for luciferase activities using Dual luciferase kits
(Promega). The ﬁreﬂy luciferase activity was then divided
by the Renilla luciferase activity in order to normalize for
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Figure 1. Scheme of the diﬀerent promoter constructions driving shLuc. The three promoter constructs tested for driving-shLuc mediated inhibition
after PEI-based transfection in the brain are shown. In (A) the H1 promoter alone; (B) CMV enhancer/promoter used alone and (C) a hybrid CMV-
H1 promoter. In each construction, the shLuc contains a TTTTT sequence required for the H1-transcription arrest and is followed by a SV40
polyadenylation sequence transcription arrest for RNA pol II in CMV- and CMV-H1 promoter constructs.
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experiments were done in triplicate.
For siTRa1 transfections, the same protocol was
adapted to transfect siTRa1 into NIH 3T3 cells
stably expressing both TRa1 and TRa2 isoforms. Three
concentrations of siTRa1 were tested ranging from 5 to
100 nM (500ml/well). In this experiment, the transfection
vector used was jetSI/DOPE, using the complexation
protocol described previously (Preparation of complexes
and gene transfer in vivo section). One day post-
transfection, cells were harvested and total RNAs
extracted. For all experiments, reverse transcription was
performed with MMLV-RT (Invitrogen) using 1mgo f
total RNA mixed with 500ng of hexamer oligonucleotides
according to the manufacturer’s instructions. Here, 1% of
cDNAs was used for quantitative PCR (Q-PCR) using
speciﬁc primers (as listed below) and SYBR-Green PCR
kit (Qiagen). Q-PCR reactions were performed at least
three times in duplicate on a DNA engine Opticon system
(MJ Research). Each point was repeated three times
(i.e. three wells for each condition) and each well was
measured in triplicate. Data were analysed by normalizing
TRa1 and TRa2 expression to that of a control gene 36B4.
The sequences of the oligonucleotides used are as follows:
TRa1 forward: 50CAGAGGGTGTGCGGAGCTGGT30;
TRa1 reverse: 50CCTGTCCAAGGGCTGGAGGGT30;
TRa2 forward: 50GCATGTTGTTCAGGGTCCGCAG
GT30;T R a2 reverse: 50GGGCTCTTCGGGCTCTGGT
GCT30; 36B4 forward: 50ACCTCCTTTCCAGGCTTT30,
36B4 reverse: 50CCCACCTTGTCTCCAGTCTTT30.
Speciﬁcity of the ampliﬁcation was optimized by determin-
ing melting curves of the amplicons.
RESULTS AND DISCUSSION
Our objectives in this study were to compare the capacities
of diﬀerent constructs to direct eﬃcient production of
shRNA in vitro and in vivo in the mammalian brain. The
expression cassettes of shRNA delivery vectors typically
exploit RNA polymerase III (Pol III) promoters (8–11),
(19–20), whilst some authors have suggested that use of a
Pol II promoter can be used successfully in certain cell
contexts using non-viral (21) or lentiviral vectors (22).
However, the use of Pol II promoters for shRNA
production is subject to certain constraints. For instance,
some authors have demonstrated a need for both a very
short distance (6bp) between the Pol II promoter and the
shRNA sequence as well as a short polyadenylation signal
(21). Others have shown that the presence of an intron
between the Pol II promoter and the shRNA sequence is
necessary for eﬃcient production (22). These constraints
do not apply to Pol III constructs. We therefore tested the
eﬃciency of a Pol III construct (H1) in diﬀerent in vivo
and in vitro situations. However, we found that the H1
promoter alone was not very eﬃcient in vivo. So we also
tried a hybrid CMV enhancer minimal promoter/H1
promoter construct (CMV/H1 construct). We chose this
strategy because this enhancer had previously been shown
to increase promoter eﬃciency in vivo, such as for the
PDGF beta promoter (23) or to increase U6-mediated
transcription of shRNAs in plasmids (24). Other fusion
promoters have also been described to increase the
shRNA production eﬃciency by recombinant SV40
derivative viruses (25) or by lentiviral vectors (26). In
our experimental set up, a construct with CMV enhancer/
promoter (CMV-shRNA) alone was used as a control for
the enhancement of the H1 promoter, knowing that in our
construct the CMV promoter was too far from the hairpin
to be eﬃcient in producing shRNA, as shown by Xia et al.
(12). Given that one of the major advantages of using an
shRNA approach is that it should be able to be exploited
to provide tissue-speciﬁc and developmental-stage-speciﬁc
gene knockdown, we examined the eﬃciencies of these
constructs in the context of the developing and the adult
mouse brain.
Design ofdifferent promoter constructs driving
the transcription ofshLuc
Three diﬀerent promoter constructs were tested for the
production of shLuc (Figure 1). The ﬁrst was a classic H1
promoter transcribing shLuc from a pSUPER vector
backbone (8). In this construction, the type III RNA
polymerase synthesizes the shRNA and is stopped by a
ﬁve-T stretch at the 30 end of the shRNA (Figure 1a). In
this H1-shLuc construct, the ﬁrst nucleotide of the shLuc
sequence is located 30bp from the TATA box of the H1
promoter (27). Second, in order to improve H1-mediated
production of shRNAs, we also constructed a CMV-H1
hybrid construct driving the production of the shRNA.
In this construction, the full enhancer and promoter
sequence of CMV has been integrated upstream of the H1
promoter (CMV-H1-shLuc). Finally, as a control to
validate that in the CMV-H1 construct, the production
of the hairpin is generated by the H1 promoter and not by
the CMV promoter, we designed a CMV-shLuc plasmid
where the CMV enhancer/promoter is too far from the
hairpin sequence to allow eﬃcient shRNA production. We
thus did not expect the CMV-shLuc plasmid to provide
any inhibition of the target luciferase (Figure 1c).
In cell culture, bothH1-shLuc and CMV-H1-shLuc trigger
efficient targetgene knockdown
We tested the eﬃciency of H1-shLuc to trigger the
inhibition of a co-transfected luciferase target gene by
RNAi in a mouse ﬁbroblastic cell line (NIH 3T3), as this
construct has been shown to be eﬀective in certain culture
conditions (28). We then compared the H1-shLuc
eﬃciency to that of the CMV-H1-shLuc in the same
cultures.
As described in the Methods section, two luciferase
reporter genes (pGL2-CMV and pRL-CMV at 30ng each)
were co-transfected in NIH 3T3 cells (Figure 2a),
along with the diﬀerent constructions described
in Figure 1. Quantiﬁcation of luciferase expression
revealed strong inhibition eﬃciency for both H1-shLuc
and CMV-H1-shLuc (0.25mg–100ml transfection
mixture). This 80% inhibition of the target gene with
H1- and CMV-H1-shLuc was stronger than obtained with
siLuc used at 70ng (Figure 4a). Similar results were
obtained using HeLa cells instead of NIH 3T3 cells
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provide inhibition of PP:RL ratio. Even though the
CMV-shLuc construct was conceived so as not to produce
hairpins we tried to verify its eventual ability to synthesize
hairpins by northern blotting. Using northern blot
protocols adapted for small size RNA inoculated from
transfected 3T3 cells, we found that the CMV-H1-shLuc
construct produced a visible 60-nt hairpin sequence,
whereas no signal of a functional hairpin detection with
the CMV-shLuc construction was seen (data not shown).
The same inhibition of an endogenous luciferase was
obtained with H1-shLuc or CMV-H1-shLuc on HeLa cells
stably expressing ﬁreﬂy luciferase, HeLa X1/5 (Figure 2b)
and HeLa 2053 cell lines which expressed PPluc under the
control of a tetracycline responsive promoter (Tet-ON)
(data not shown). As shown in Figure 2, we observed a
strong inhibition of PP:RL ratio in the presence of H1- or
CMV-H1-shLuc, both constructs being able to inhibit
endogenous gene expression.
H1-shLuc providesonly limited inhibition oftarget gene
expression in thenewborn mouse brain
The ﬁrst construction tested in vivo was the H1-shLuc
plasmid, which was tested in the newborn mouse brain
model. This model provides a useful paradigm for
assessing the performance of vectors and plasmids in an
in vivo context (29,30). After co-transfection of this
construction along with target (PPluc) and control
(RRluc) luciferase reporter genes in the lateral ventricles
of newborn mice, we found that the H1-shLuc-driven
inhibition of PPluc was very limited (Figure 3a). In fact,
inhibition of target gene expression never exceeded 25% at
any time point tested (from 16 to 72h) (Figure 3b).
This result contrasts with the high eﬃciency of
pSUPER-p53 as ﬁrst described by Brummelkamp et al.,
where an H1-mediated transcription of a p53-targeting
shRNA leads to the strong knockdown of target gene
expression in cell culture (8). Thus, it is worth noting that
in our experiments in HeLa cells, the PP:RR ratio was
decreased by 480% in the presence of H1-shLuc, a level
that is  2.5 times greater than the inhibition obtained in
the mouse brain (25%) with the identical construction.
This divergence suggests that the eﬃciency of shRNA-
carrying plasmids in terms of target gene inhibition is cell
context-dependent and supports the idea that each tissue
and condition (in vivo versus in vitro) requires optimiza-
tion for the use of shRNAs-triggered RNAi. Two
hypotheses could explain this diﬀerence in the eﬃciency
of H1-shRNAs in the mouse brain and in cell cultures.
The ﬁrst could be a lower copy number of shRNAs
produced by H1 in the brain compared to cell cultures.
The second possibility could be the lower eﬃciency of
Dicer-induced processing of the hairpin in the brain that
would lead to less eﬃcient production of shRNA
molecules for RNAi triggering.
The hybrid CMV-H1construct provides thebest inhibition
oftarget geneexpression inthe mammalian brain
We next tested the CMV-H1-shLuc construction in the
newborn mouse brain and found that it triggered 450%
inhibition of PP:RRluc ratio (Figure 4a). The maximal
inhibition obtained with this hybrid promoter construc-
tion was observed at 50h post-transfection (Figure 4b)
and was still visible at 72h post-transfection (data not
shown).
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Figure 2. H1- and CMV-H1-shLuc show equal eﬃciency in cell cultures. (A) Plasmids containing shLuc (white bars) or control sequences (black
bars) or siRNAs against PP luciferase (grey bars) were transfected in NIH 3T3 cells as described in the methods section, along with two reporter
genes (pGL2-CMV and pRL-CMV). Only H1-shLuc and CMV-H1-shLuc lead to an inhibition, like siLuc. (B) HeLa X1/5 cells stably expressing
ﬁreﬂy luciferase were transfected by the diﬀerent plasmid constructions described in (a) or with siRNAs. As in NIH 3T3 cells, only H1-shLuc, CMV-
H1-shLuc and siLuc provided signiﬁcant inhibition of the endogenous luciferase expression. Means SEM are shown. NS¼‘not signiﬁcant’;
 P 0.05;
  P 0.01;
   P 0.001 (n¼3 samples per group). This graph is for a single representative experiment, which was repeated three times
giving similar results.
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level of inhibition was not as strong as that observed in the
newborn brain. In this situation, the CMV-H1-shLuc
construct provided  25% inhibition of PP:RRluc ratio
compared to the control group. This inhibition was
constant from 48 to 96h post-transfection (Figure 4c).
Note that in the adult mouse brain, the presence of the
H1-shLuc construction did not produce any signiﬁcant
inhibition of its target luciferase gene (Figure 4c grey
columns). So in the newborn and in the adult mouse brain
context, the presence of the CMV enhancer upstream of
the H1 type III promoter driving the synthesis of a hairpin
sequence provides a signiﬁcant improvement in terms of
inhibitory eﬀect induced by the shRNA.
Whilst this work was in progress, a paper appeared
describing the use a PolIII promoter appended to a
CMV enhancer (31), which is similar but distinct from our
CMV-H1-shLuc construction, in which the entire
CMV enhancer/promoter is located upstream of the
H1-promoter. A further diﬀerence is that Ong et al.
(2005) used the hybrid promoter ﬁrst in plasmid con-
structs, in vitro, then in baculovirus-mediated infection of
shRNAs in vivo in rat brains. In contrast, our results are
obtained using non-viral constructs both in vitro and
in vivo. Thus, given the generally greater facility of
creating and using non-viral constructs, our ﬁndings that
the hybrid promoter is optimal in vivo with plasmid-based
constructs will open up new possibilities for applying
shRNA technology in new settings.
CMV-shLuc isinefficient in boththe newbornand inthe
adult mouse brain
In order to test whether the increased inhibitory
eﬃciency of the CMV-H1 hybrid promoter was due
to the CMV enhancer/promoter alone, we injected
CMV-shLuc along with the two luciferase reporter genes
in the brains of newborn mice. We found no inhibition of
the target gene in the CMV-shLuc groups at any dose
tested, compared to the control groups (Supplementary
Figure 1). This construction was also tested in the adult
mouse brain, where no inhibition was visible (data not
shown). This result supports the idea that in the CMV-H1
hybrid promoter, the CMV only plays the role of an
enhancer, and that the transcription of the shRNA is
mediated by the type III promoter H1 alone and not by
the CMV enhancer/promoter [as observed in (31)]. The
position of the CMV promoter start site,4100bp from the
hairpin sequence, explains the lack of eﬃcient shRNA
production, as demonstrated by Xia et al. (12).
SiRNA or shRNA knockdownof thyroidhormone receptor
a1relieves T3-dependent repression ofCyclinD1-luciferase
transcription
After having demonstrated that the presence of a CMV
enhancer/promoter upstream of an H1 promoter strongly
increases the inhibition eﬃciency of shRNAs, we exploited
this technology to follow physiological regulations in the
mouse brain in vivo. Previous studies revealed both the
role of thyroid hormones (TH) in NSC cycling in vivo (32),
and the speciﬁc role of TRa1 as the mediator of this
regulation. We hypothesized that the action of T3 on NSC
cycling may implicate CyclinD1 and assessed whether this
regulation was mediated or not by TRa1.
Indeed, CyclinD1 is known to be a T3-regulated gene.
But T3-dependent regulations can vary as a function
of tissue and developmental stage. For instance,
T3 up-regulates CyclinD1 in the pancreas (33) and
liver (34), while T3 represses CyclinD1 transcription in
neuroblastoma cells (35). In order to assess CyclinD1
regulation in neurogenic areas of the brains of newborn
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Figure 3. H1-shLuc provides only limited inhibition of a co-transfected
luciferase reporter gene in vivo: dose dependence and time course. (A)
Two luciferase reporter genes-containing plasmids (pGL2-CMV and
pRL-CMV) were co-transfected by stereotaxic injection into the lateral
ventricles of newborn mice brains, along with H1-shLuc construction at
diﬀerent concentrations (grey bars) ranging from 0.1 to 0.4mg/ml, or
with an irrelevant H1-shRNA as a control (black bar). The sequence of
the shLuc hairpin is directed against its target gene PP-luc and has no
homology with RL-luc, which serves as a control for transfection. The
graph represents the normalization of PP-luc against RL-luc expression.
In the presence of H1-shLuc at all doses tested, we observed a decrease
of PP:RL ratio of  25%. (B) The time course of H1-shLuc eﬃciency
shows that inhibition of target gene expression does not vary between
16 and 48h. At 72h, no signiﬁcant inhibition is found. Black and white
bars correspond to 0.86mg/hemisphere of irrelevant H1-shRNA and
H1-shluc constructions, respectively. Means SEM are shown.
NS¼‘not signiﬁcant’;
 P 0.05;
  P 0.01;
   P 0.001. n¼10 per
group.
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the lateral ventricles of hypothyroid animals. Luciferase
expression of the reporter gene was followed 18h after T3
treatment compared to controls (Figure 5b). We observed
a signiﬁcant decrease of CyclinD1-luciferase expression in
T3-treated animals. Thus, CyclinD1 transcription is
negatively regulated in neurogenic areas lining the lateral
ventricles of newborn mice brains.
In order to assess whether TRa1 is involved in this
T3-mediated repression of CyclinD1 expression, we
designed siRNAs directed against TRa1, and checked
their eﬃciency and their speciﬁcity on 3T3 culture cells
stably expressing TRa1 and TRa2 (Figure 5a). Using
quantitative real-time RT-PCR, the siTRa1 designed was
shown to speciﬁcally inhibit the expression of TRa1 and
did not aﬀect the expression of TRa2at any dose tested
(Figure 5a). By co-transfecting these siTRa1 along with
the CyclinD1-luciferase reporter gene in the brain of
euthyroid newborn mice, we observed a signiﬁcant and
dose-dependent increase in CyclinD1-luciferase expression
(Figure 5c). The same result was obtained when
using plasmids coding for shTRa1 under the control of
a CMV-H1 construct: we observed a signiﬁcant
up-regulation of CyclinD1-luciferase expression in
CMV-H1-shTRa1-injected mice brains (Figure 5d).
These data suggest ﬁrst, that PEI-vectorized shRNA
technology can be used to examine physiological regula-
tions in vivo and second, that TRa1 may play a role in the
regulation of CyclinD1 by thyroid hormones. Note that
we observed the same increase in CyclinD1-luciferase
expression following co-injection of either 200nM of
siTRa1 (Figure 5c) or by 0.5mg of CMV-H1-shTRa1
plasmid per hemisphere (Figure 5d).
CONCLUDING REMARKS
The results presented here show that PEI-based delivery of
shLuc to the newborn or the adult mouse brain is optimal
when used with a plasmid construct bearing a hybrid
CMV enhancer–H1 promoter. The system was most
eﬃcient in the newborn brain, reaching 50% inhibition
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Figure 4. A CMV-H1 hybrid construct driving shLuc provides enhanced inhibition of a co-transfected target gene in the newborn (a and b) and in
the adult (c) mouse brain. (A) Dose dependence of CMV-H1-shLuc eﬃciency. The inhibition eﬃciency of CMV-H1-shLuc was tested at diﬀerent
doses ranging from 0.1 to 0.4mg/ml. After co-transfection of pGL2-CMV and pRL-CMV along with 0.4mg/ml of CMV-H1-shLuc (i.e. 0.8mg/
hemisphere), we observed up to 50% inhibition of the targeted luciferase expression. This level of inhibition was obtained at 48h post-transfection.
(B) Time course eﬃciency of CMV-H1-shLuc. Signiﬁcant inhibition of the target gene with 0.4mg/ml of CMV-H1-shLuc was seen at all times tested.
The maximal level of inhibition (50%) was seen at 50h post-transfection. (C) In the adult brain, H1-shLuc provided no inhibition of PP:RL ratio
(grey bars) compared to controls (black bars). CMV-H1-shLuc leads to 25% inhibition of the target gene at 72h post-transfection (white bars) and
up to 112h post-transfection (data not shown). Means SEM are shown. NS¼‘not signiﬁcant’;
 P 0.05;
  P 0.01;
   P 0.001. n¼10 injected
hemispheres per group.
PAGE 7 OF 9 Nucleic Acids Research, 2007, Vol. 35, No. 9 e65of target gene expression. This level of inhibition is less
than that obtained in the newborn mouse brain when
siRNA against luciferase is delivered with cationic lipids
(16). However, as cationic-lipid-delivered siRNA in the
adult brain is ineﬃcient (data not shown), we propose that
this PEI-based delivery of shLuc under a hybrid promoter
will become a useful tool for performing gene knockdown
in the brain at diﬀerent developmental stages. As this non-
viral delivery technology combines high eﬃciency with the
use of non-immunogenic components, it could also prove
to be useful in terms of therapeutic applications. Indeed,
the current demonstration that it can be used to dissect the
role of diﬀerent transcription factors in regulating speciﬁc
genes, already opens up new possibilities for reverse
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Figure 5. CyclinD1 transcriptional repression by T3 implicates thyroid hormone receptor a1 (TRa1). (A) Quantiﬁcation of TRa1 and TRa2 mRNAs
in 3T3 cells transfected by 5–100nM of siTRa1 (500ml per well). The total amount of TRa1 and TRa2 mRNA in each condition was normalized to
that of 36B4 (a control gene) in the same group. Note that only TRa1, and not TRa2 expression, is inhibited by shTRa1( B) CyclinD1-luciferase
reporter gene expression in vivo is down-regulated in the presence of T3. CyclinD1-luciferase complexed by L-PEI was injected into the lateral
ventricles of hypothyroid newborn mice. Then either a saline solution (NaCl 0.9%, control) or T3 (2.5mg/kg body weight) was injected
subcutaneously (see Methods section). Luciferase assays were performed 18h later. T3 treatment induces a strong decrease in cyclinD1-luciferase
expression compared to the control group. (C) Diﬀerent doses (ranging from 2 to 200 nM) of siRNAs directed against TRa1 (siTRa1) were co-
injected along with the CyclinD1-luciferase plasmid in the lateral ventricles of euthyroid newborn mice, inducing a strong activation of CyclinD1-
luciferase expression. (D) The same experiment as described in (c) was performed by using plasmids coding for shTRa1 instead of siTRa1. The
diﬀerent doses of shTRa1-coding plasmid tested ranged from 0.1 to 0.25mg/hemisphere. We observed a similar result to that seen with siTRa1, i.e. a
strong de-repression of CyclinD1-luciferase following knockdown of TRa1. Means SEM are shown, n¼20 injected hemispheres per group. Each
experiment was performed at least twice, providing similar results. NS¼‘not signiﬁcant’;
 P 0.05;
  P 0.01;
    P 0.001 (n¼3 samples per
group).
e65 Nucleic Acids Research, 2007, Vol. 35, No. 9 PAGE 8 OF9genetic studies focused on speciﬁc target tissues at deﬁned
developmental stages.
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